High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies

Affiliations

• ¹ Department of Internal Medicine H, Rambam Health Care Campus, Haifa.
• ² Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa.
• ³ Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa.
• ⁴ Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa.
• ⁵ Blood Bank and Platelet Immunology Laboratory, Rambam Health Care Campus, Haifa.
• ⁶ Department of Internal Medicine H, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa.
• ⁷ Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa. o_katz@rmc.gov.il.